Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 26.77% is 212% above its 5-year average of -23.89%, near the high end of its 5-year range (-266.00%–60.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 21.14% below its 12-month average of 33.94%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 26.77%.
RETURN ON EQUITY (ROE)
26.77%
RETURN ON EQUITY (ROE) AVG TTM
33.94%
RETURN ON EQUITY (ROE) AVG 3Y
-68.44%
RETURN ON EQUITY (ROE) AVG 5Y
-23.89%
RETURN ON EQUITY (ROE) AVG 10Y
-23.71%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-21.14%
CURRENT VS 3Y AVG
+139.11%
CURRENT VS 5Y AVG
+212.05%
CURRENT VS 10Y AVG
+212.88%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+163.72%
vs the sector median at left
Zevra Therapeutics, Inc.
Market Cap
$634.30M
Return on Equity (ROE)
26.77%
TTM Avg
33.94%
3Y Avg
-68.44%
5Y Avg
-23.89%
Market Cap
$632.16M
Return on Equity (ROE)
-471.98%
TTM Avg
-147.16%
3Y Avg
-120.43%
5Y Avg
-93.49%
Market Cap
$630.63M
Return on Equity (ROE)
-17.01%
TTM Avg
-22.91%
3Y Avg
-17.12%
5Y Avg
-14.58%
Market Cap
$638.20M
Return on Equity (ROE)
-41.56%
TTM Avg
-67.38%
3Y Avg
-49.66%
5Y Avg
-56.07%
Market Cap
$619.15M
Return on Equity (ROE)
-97.31%
TTM Avg
-116.17%
3Y Avg
-82.05%
5Y Avg
-65.68%
Market Cap
$656.59M
Return on Equity (ROE)
-43.95%
TTM Avg
-29.61%
3Y Avg
-34.61%
5Y Avg
-30.48%
Market Cap
$611.57M
Return on Equity (ROE)
-24.06%
TTM Avg
-36.09%
3Y Avg
-34.99%
5Y Avg
-44.03%
Market Cap
$657.89M
Return on Equity (ROE)
N/A
TTM Avg
385.53%
3Y Avg
385.53%
5Y Avg
385.53%
Market Cap
$660.29M
Return on Equity (ROE)
-108.93%
TTM Avg
-72.41%
3Y Avg
-64.95%
5Y Avg
-55.74%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zevra Therapeutics, Inc. (ZVRA) | $634.30M | 26.77% | 33.94% | -68.44% | -23.89% |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -471.98% | -147.16% | -120.43% | -93.49% |
| OmniAb, Inc. (OABI)vs › | $630.63M | -17.01% | -22.91% | -17.12% | -14.58% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | -41.56% | -67.38% | -49.66% | -56.07% |
| SOPHiA GENETICS S.A. (SOPH)vs › | $619.15M | -97.31% | -116.17% | -82.05% | -65.68% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | -43.95% | -29.61% | -34.61% | -30.48% |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | -24.06% | -36.09% | -34.99% | -44.03% |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | N/A | 385.53% | 385.53% | 385.53% |
| Annexon, Inc. (ANNX)vs › | $660.29M | -108.93% | -72.41% | -64.95% | -55.74% |
| Helus Pharma Inc. (HELP)vs › | $666.95M | -75.79% | -55.51% | -59.06% | -60.41% |
ROE
26.8%
ROA
19.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 26.77% |
| 2026-03-31 | 60.36% |
| 2025-12-31 | 53.82% |
| 2025-09-30 | 26.53% |
| 2025-06-30 | 2.26% |
| 2025-03-31 | -224.24% |
| 2024-12-31 | -266.00% |
| 2024-09-30 | -121.72% |
| 2024-06-30 | -191.10% |
| 2024-03-31 | -91.60% |
| 2023-12-31 | -66.78% |
| 2023-09-30 | -52.14% |
| 2023-06-30 | -45.88% |
| 2023-03-31 | -74.08% |
| 2022-12-31 | -55.30% |
| 2022-09-30 | -37.56% |
| 2022-06-30 | -30.60% |
| 2022-03-31 | -0.10% |
| 2021-12-31 | -6.73% |
| 2021-09-30 | -8.13% |
| 2021-06-30 | -9.15% |
| 2021-03-31 | -20.54% |
| 2015-09-30 | -213.29% |
